

ASX: CVB

19 March 2026

CurveBeam AI Appoints Experienced Global Orthopaedic Industry Executive, Mr Patrick Fisher as Independent Non-Executive Director

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB “CurveBeam AI” or the “Company”), a fully integrated developer and manufacturer of point-of-care specialised weight bearing CT imaging (WBCT) equipment, supported by a range of AI-enabled SaaS-based clinical assessment solutions, is pleased to announce the appointment of Mr Patrick Fisher as an Independent Non-Executive Director of the Company, effective immediately.

Mr Fisher is US-based and a highly experienced global orthopaedic industry executive with more than two decades of leadership experience across global medical device organisations. He currently serves as President of Global Biologics and Limb Reconstruction at Orthofix and has previously held senior leadership roles at Stryker and Wright Medical Group, where he was involved across knee, hip, and foot & ankle segments.

Mr Fisher brings deep expertise in global orthopaedic markets, commercial strategy, capital equipment deployment, and surgeon engagement. His experience scaling businesses within complex regulatory and reimbursement environments will provide valuable insight as CurveBeam AI continues to expand adoption of its weight bearing CT technology in the United States and across the globe.

Herewith the Company provides a Q&A video interview with Mr Fisher for shareholders to learn more about him and why he has joined the CurveBeam AI board of directors.

<https://youtu.be/ZedKzY3NY6g>

Chair of CurveBeam AI, Mr Robert Lilley said: “We are delighted to welcome Patrick to the Board. His experience across leading orthopaedic organisations, combined with his understanding of the US and global hospital and group surgeon practice landscape, will be instrumental as we execute our next phase of commercial growth. Patrick’s appointment further strengthens our strategic capability in the largest growth market and reinforces the Company’s commitment to expanding its US and global footprint.”

Mr Fisher commented: “CurveBeam AI is defining weight bearing musculoskeletal imaging at a pivotal time for orthopaedics. I am excited to join the Board and collaborate with the leadership team to manage strategic commercial partners, expand market adoption, deepen clinical partnerships, and drive sustained growth across the U.S. and internationally.”

The board has approved an initial grant of 2.5 million share rights vesting over 3 years, and annual remuneration of US\$50,000 in cash fees and US\$80,000 in annual share right grants (with annual share right grants subject to shareholder approval).

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non-weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au